NanoPhoria is a technology company.
NanoPhoria has raised $98.0M across 1 funding round.
NanoPhoria has raised $98.0M in total across 1 funding round.
NanoPhoria has raised $98.0M in total across 1 funding round.
NanoPhoria's investors include Apollo Health Ventures, Broadview Ventures, Humboldt Fund, Soffinova Partners.
NanoPhoria is a preclinical-stage biotech company developing inhalable cardiovascular treatments using a proprietary non-viral nano-delivery platform for biologics. Based in Milan, Italy, it focuses on tissue-directed delivery of therapeutic peptides and RNAs via inorganic calcium-phosphate nanoparticles, formulated for inhalation or other routes.[1][2][3] The lead product, NP-MP1, is an inhalable nano-in-micro formulation delivering a first-in-class peptide that modulates calcium channels to treat Heart Failure with reduced Ejection Fraction (HFrEF), a chronic condition affecting millions worldwide.[1][3] NanoPhoria serves patients with underserved cardiac conditions, solving the problem of targeted delivery to cardiomyocytes—previously inaccessible with existing treatments—through lung-to-heart technology that has shown promise in preclinical models.[1][3] The company has strong growth momentum, raising €83.5M ($98M) in an initial Series A closing led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, plus €17.5M from the European Innovation Council, funding IND-enabling trials, clinical development, manufacturing scale-up, and pipeline expansion.[2][3][5]
NanoPhoria was founded in 2022 as a spin-off from Italy's National Research Council (CNR), the country's largest public research institution. The four founders bring complementary backgrounds and remain actively involved, with the idea emerging from converging scientific expertise in nanotechnology and cardiovascular biology.[2][3][6] A pivotal moment came with early validation of their inorganic nanoparticle platform, leading to investments like Sofinnova Partners' backing via its Telethon strategy, which spotlights top Italian science.[2] Key milestones include publishing a groundbreaking study in a major cardiology journal, appointing Dr. Suman Shirodkar as chair and Prof. Michael Davidson as a non-executive board member, and securing major grants and funding to propel preclinical work toward clinical stages.[2]
NanoPhoria stands out in biotech through these key strengths:
NanoPhoria rides the wave of nanotechnology convergence with biologics delivery, particularly non-viral alternatives to gene therapies, amid rising demand for targeted cardiovascular treatments as heart disease remains a leading global killer.[1][3] Timing is ideal with Europe's biotech surge—fueled by EIC grants and VC focus on platform technologies—positioning Italy's research ecosystem (via CNR spin-offs) as a hub for innovation.[2][5][6] Market forces like aging populations, HFrEF's massive burden, and limitations of current oral/intravenous drugs favor inhalable solutions that bypass systemic issues for direct tissue action.[1][3] By advancing nano-in-micro tech, NanoPhoria influences the ecosystem, inspiring similar platforms and drawing capital to European cardio-biotech, potentially reshaping delivery for peptides/RNAs in chronic diseases.[2][3]
NanoPhoria's next milestones include IND submission, Phase 1 trials for NP-MP1, and pipeline expansion using its platform for additional indications. Trends like AI-optimized nanoparticles, combo therapies, and regulatory fast-tracks for heart failure will accelerate progress, with influence growing via board expertise and partnerships.[2][3] As it transitions from preclinical to clinic, expect broader adoption of its non-viral tech, transforming underserved cardiac care and solidifying its role as a Milanese biotech leader—pioneering inhalable hope for millions with HFrEF.[1][3]
NanoPhoria has raised $98.0M across 1 funding round. Most recently, it raised $98.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $98.0M Series A | Apollo Health Ventures, Broadview Ventures, Humboldt Fund, Soffinova Partners |